Overall, these data implied that in addition to a general prognostic impact in patients with MDS, WT1-mRNA expression seemed to refine the prediction of disease progression particularly in patients with IPSS-R very low/low and intermediate risk. The gene discussed is WT1; the disease is myelodysplastic syndrome.